Brief: Tiziana Announces Discovery Of New Immune Biomarkers In Multiple Sclerosis Patients Treated With Nasal Foralumab
22/01/2025 21:53
Jan 22 (Reuters) - Tiziana Life Sciences Ltd TLSA.O :
* TIZIANA LIFE SCIENCES ANNOUNCES DISCOVERY OF NEW IMMUNE
BIOMARKERS IN MULTIPLE SCLEROSIS PATIENTS TREATED WITH NASAL
FORALUMAB
* TIZIANA LIFE SCIENCES LTD - GENE EXPRESSION CHANGES
DETECTED
THREE MONTHS AFTER FORALUMAB DOSING
Source text: ID:nGNX6FqjN3
Further company coverage: TLSA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tiziana Life Sciences
See all newsBrief: Tiziana Announces New Positive Clinical Data For Intranasal Foralumab In Non-Active Secondary Progressive Multiple Sclerosis
U.S. STOCKS ON THE MOVE -Viatris, Clear Secure, Bicara
U.S. STOCKS ON THE MOVE-Sharps Technology, Whirlpool, Applovin
U.S. STOCKS ON THE MOVE-Oracle, Vanda, Keysight
Tiziana Life Sciences rises as nasal MS drug shows promise in early study